Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap
This article was originally published in The Gray Sheet
Executive Summary
Chugai's decision to spin off its wholly-owned diagnostic subsidiary Gen-Probe following a merger with Roche's Japanese unit, Nippon Roche, will preserve worldwide competition between Roche's Cobas AmpliScreen nucleic acid test (NAT) line and Chiron's Procleix NAT, developed with Gen-Probe